The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5, 2010, Pages 661-668

  Arends, S ^a   Lebbink, H R ^a   Spoorenberg, A ^b   Bungener, L B ^c   Roozendaal, C ^c   Van Der Veer, E ^c   Houtman, P M ^b   Griep, E N ^b   Limburg, P C ^a,c   Kallenberg, C G M ^a   Wolbink, G J ^d   Brouwer, E ^a  

^a Rheumatology and Clinical Immunology   (Netherlands)

^b Rheumatology   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

Ankylosing spondylitis; Antibody formation; Autoantibodies; Clinical response; TNF blocking therapy

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; INFLIXIMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ASSESSMENT; DISEASE ACTIVITY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650550839     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. BRAUN J, KALDEN JR: Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(Suppl. 55): S164-7.
2. CALIN A, DIJKMANS BA, EMERY P et al.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
3. VAN der HEIJDE D, DIJKMANS B, GEUSENS P et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (AS-SERT). Arthritis Rheum 2005;52:582-91.
4. VAN der HEUDE D, SCHIFF MH, SIEPER J et al.: Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922-9.
5. BARTELDS GM, WIJBRANDTS CA, NURMO-HAMED MT et al.: Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
6. WOLBINK GJ, VIS M, LEMS W et al.: Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-5.
7. WOLBINK GJ, AARDEN LA, DIJKMANS BA: Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211-5.
8. DE VRIES MK, WOLBINK GJ, STAPEL SO et al.: Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252-4.
9. DE VRIES MK, VAN der HORST-BRUlNSMA IE, NURMOHAMED MT et al.: Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:531-5.
10. DE VRIES MK, BROUWER E, VAN der HORST-BRUINSMA IE et al.: Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009;68:1787-8.
11. CALVO-ROMERO JM, ROMERO-REQUENA J, AREVALO-LORIDO JC: Antineutrophil cytoplasmic antibodies (ANCA) in ankylosing spondylitis. Clin Exp Rheumatol 2003;21:528.
12. DE RYCKE L, BAETEN D, KRUITHOF E, VAN den BOSCH F, VEYS EM, DE KEYSER F: Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005;52:2192-201.
13. BACQUET-DESCHRYVER H, JOUEN F, QUIL-LARD M et al.: Impact of three anti-TN-Falpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 2008;28:445-55.
14. FERRARO-PEYRET C, COURY F, TEBIB JG, BIENVENU J, FABIEN N: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004;6: R535-R543.
15. GONNET-GRACIA C, BARNETCHE T, RICHEZ C, BLANCO P, DEHAIS J, SCHAEVERBEKE T: Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 2008;26:401-7.
16. VAN der LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
17. BRAUN J, DAVIS J, DOUGADOS M, SIEPER J, VAN der LINDEN S, VAN der HEIJDE D: First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
18. ANDERSON JJ, BARON G, VAN der HEIJDE D, FELSON DT, DOUGADOS M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
19. LUKAS C, LANDEWE R, SIEPER J et al.: Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
20. VAN der HEIJDE D, LIE E, KVIEN TK et al.: ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-8.
21. VAN der WOUDE FJ, RASMUSSEN N, LO-BATTO S et al.: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;1:425-9.
22. WIIK A: Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS 1989;97(Suppl. 6):12-3.
23. VAN der GIESSEN M, HUITEMA MG, CO-HEN TERVAERT JW, KALLENBERG CGM: A technical note on the routinely performed ANCA detection. APMIS 1989;97(Suppl. 6):37.
24. BRAUN J, DEODHAR A, DIJKMANS B et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008;59:1270-8.
25. DIJKMANS B, EMERY P, HAKALA M et al.: Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36:1256-64.
26. DE RYCKE L, BAETEN D, KRUITHOF E, VAN den BOSCH F, VEYS EM, DE KEYSER F: The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005;14:931-7.